Press Room

Webinar: ASDs by Spray Drying: Process Development & Scale-Up

Start
Wednesday, March 22, 2023 - 16:00
Location: online
Webinar - ASDs Amorphous Solid Dispersions by Spray Drying | Hovione

This is the second session of a three-part webinar series on Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management.

 

Watch On-demand. 

Gated content. Registration is required.

 

Learn more about this webinar series here.

 

Featured Hovione experts in this webinar
Clara Sá Couto - Manager, R&D Oral Drug Product - Process Development Team | Hovione
José Luís Santos, Ph.D. Director, Technology Intensification | Hovione
Clara Sá Couto, Ph.D.

Manager, R&D Oral Drug Product,

Process Development Team
José Luís Santos, Ph.D.

Director, Technology Intensification

 

​​​​Clara Sá Couto and José Luís Santos will describe the best practices to transition ASD formulations developed in the laboratory into a reliable industrial process, based upon proven methodologies for process development and scale-up, guaranteeing lean and material sparing approaches. 

The webinar will cover industry standard QbD principles, mathematical models and process development methodologies that benefit from extensive development and manufacturing experience. Existing lab assets will be presented, including a customized spray dryer that can mimic large scale powder properties. Finally, the speakers will guide you through a model-based methodology to establish a design space, to prepare the process for validation and commercial supply.

 

Your Key Learning Objectives: 

  • Understand what to consider for the process development and scale-up of ASD formulations manufactured by spray drying to gain a robust process for validation and commercial supply;
  • ​Discover how to develop an industrially reliable ASD formulation in the lab based on advanced mathematical model to be able to generate optimized process conditions that guarantee seamless scaling-up;
  • Learn how to leverage previous experience, databases, and mathematical models to improve process development and troubleshooting, and to establish an optimized design space to enable flexible manufacturing strategies.

 

Who Should Attend: 

This webinar is suitable for anyone working in formulation and process development of amorphous solid dispersions, procurement, and outsourcing teams or project managers, who are interested in understanding the end-to-end process for developing and scaling-up an ASD by spray drying.

 

 

Watch On-demand. 

Gated content. Registration is required.

 

Do you have a challenging project needing differentiating technologies and an innovative approach?

Get in touch today

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026